| Literature DB >> 24925196 |
Margaret von Mehren1, R Lor Randall1, Robert S Benjamin1, Sarah Boles1, Marilyn M Bui1, Ephraim S Casper1, Ernest U Conrad1, Thomas F DeLaney1, Kristen N Ganjoo1, Suzanne George1, Ricardo J Gonzalez1, Martin J Heslin1, John M Kane1, Joel Mayerson1, Sean V McGarry1, Christian Meyer1, Richard J O'Donnell1, Alberto S Pappo1, I Benjamin Paz1, John D Pfeifer1, Richard F Riedel1, Scott Schuetze1, Karen D Schupak1, Herbert S Schwartz1, Brian A Van Tine1, Jeffrey D Wayne1, Mary Anne Bergman1, Hema Sundar1.
Abstract
Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24925196 DOI： 10.6004/jnccn.2014.0080
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908